North American Intrauterine Contraceptive Devices (IUCD) Market – Opportunities and Forecast, 2014 – 2022 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “North
American Intrauterine Contraceptive Devices (IUCD) Market –
Opportunities and Forecast, 2014 – 2022”
report to their

Intrauterine contraceptive device (IUCD) is a reversible, long acting
T-shaped device, which is inserted into uterus for contraception
purposes. It prevents fertilization of eggs in the uterus and thus,
helps to avoid pregnancy. IUCDs can provide contraception for 3 to12
years after insertion into the vagina, depending on type of ICUD and
preference. IUCDs do not interfere in sexual intercourse or
breastfeeding and can be used as an effective alternative to
contraceptive pills. It can be inserted immediately after delivery or
abortion. Women are able to retain fertility rapidly after its removal.
IUCDs are widely used due to lower failure rates and cost effective
nature for long-term use.

The major driving factors of the North American intrauterine
contraceptive devices market are the increasing rate of unplanned
pregnancies, especially in young females and the rising need for
controlling population growth. Similarly, IUCD provides several
advantages such as fewer side effects over oral contraception, which is
a major driving factor. In addition, favorable government initiatives
would further provide boost to the market. For instance, the
implementation of the Affordable Care Act (ACA), supportive private
firms initiatives for reducing expenses related to abortion, and funds
for IUCD products have augmented the market growth.

The report provides, comprehensive competitive analysis and profiles of
major market players such as Bayer Healthcare AG, Teva Pharmaceutical
Industries Ltd., Actavis PLC, Medicines360, Trimedic Supply Network
Ltd., Medisafe Distribution Inc., and Pace Pharmaceuticals Inc. have
been provided in this report. The leading market players have adopted
mergers & acquisitions and partnerships as one of the key developmental
strategy., in order to gain strong foothold of market.

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Women’s